Prenetics Global (NASDAQ:PRE) Stock Price Down 1.6% – Should You Sell?

Prenetics Global Limited (NASDAQ:PRE) shares fell 1.6% on Friday . The company traded as low as $5.70 and last traded at $5.70. 1,032 shares were traded during trading, a decline of 98% from the average session volume of 48,158 shares. The stock had previously closed at $5.79.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $9.00 price target on shares of Prenetics Global in a report on Wednesday, December 4th.

Prenetics Global Stock Down 1.6 %

The company’s 50-day moving average is $4.88 and its 200-day moving average is $5.12. The stock has a market cap of $52.08 million, a price-to-earnings ratio of -1.43 and a beta of -0.18.

Prenetics Global (NASDAQ:PRE) last issued its earnings results on Monday, October 7th. The company reported ($0.88) earnings per share (EPS) for the quarter. The company had revenue of $5.94 million during the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%. On average, research analysts forecast that Prenetics Global Limited will post -3.3 earnings per share for the current year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.